Prognostic Significance of CTCs and CSCs of Tumor Drainage Vein Blood in Dukes' Stage B and C Colorectal Cancer Patients

Overview

Journal Oncol Rep

Specialty Oncology

Date 2012 Jan 24

PMID 22267181

Citations 19

Authors

Ryu Shimada

Hisae Iinuma

Takuya Akahane

Atsushi Horiuchi

Toshiaki Watanabe

Affiliations

Soon will be listed here.

Abstract

The clinical significance of circulating tumor cells (CTCs) including cancer stem cells (CSCs) (CTC/CSC) in the tumor drainage vein blood of patients with colorectal cancer (CRC) is unclear. In this study, we investigated the prognostic value of CTC/CSC that express carcinoembryonic antigen (CEA) cytokeratin 19 (CK19), CK20 and/or CD133 (CEA/CK/CD133) mRNA in the tumor drainage blood of CRC patients with Dukes' stage B and C. We examined tumor drainage blood from 197 patients with Dukes' stage B and C CRC. CTCs that expressed CEA, CK19, CK20 and CD133 mRNA were detected using the quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. Each mRNA level was normalized with GAPDH mRNA levels. In the relationship between the expression of CEA/CK/CD133 in the tumor drainage blood and clinicopathological factors, a significant correlation was observed between CEA/CK/CD133 expression and Dukes' stage (p<0.041). In CRC patients with Dukes' stage B and C, disease-free (DFS) and overall survival (OS) of patients with CEA/CK/CD133 positive in the tumor drainage blood were significantly worse than that of marker gene negative patients. In contrast, in patients with Dukes' stage A, no significant differences were shown between these groups. By Cox progression analysis, it was shown that CEA/CK/CD133 mRNA in tumor drainage blood was an independent prognostic factor for DFS and OS in patients with Dukes' stage B and C. These results suggest that detecting CEA/CK/CD133 mRNA in tumor drainage blood by the real-time RT-PCR method would have a prognostic value in CRC patients with Dukes' stage B and C.

Citing Articles

Targeted liquid biopsy for brain tumors.

Izhar M, Ahmad Z, Moazzam M, Jader A J Liq Biopsy. 2025; 6:100170.

PMID: 40027302 PMC: 11863980. DOI: 10.1016/j.jlb.2024.100170.

Nanobiotechnology augmented cancer stem cell guided management of cancer: liquid-biopsy, imaging, and treatment.

Sun S, Yang Q, Jiang D, Zhang Y J Nanobiotechnology. 2024; 22(1):176.

PMID: 38609981 PMC: 11015566. DOI: 10.1186/s12951-024-02432-5.

Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments.

Aramini B, Masciale V, Arienti C, Dominici M, Stella F, Martinelli G Cancers (Basel). 2022; 14(10).

PMID: 35626011 PMC: 9139858. DOI: 10.3390/cancers14102408.

Detection of circulating tumour cells in colorectal cancer: Emerging techniques and clinical implications.

Yadav A, Kumar A, Siddiqui M World J Clin Oncol. 2022; 12(12):1169-1181.

PMID: 35070736 PMC: 8716996. DOI: 10.5306/wjco.v12.i12.1169.

Circulating tumor cells: biology and clinical significance.

Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q Signal Transduct Target Ther. 2021; 6(1):404.

PMID: 34803167 PMC: 8606574. DOI: 10.1038/s41392-021-00817-8.

References

Hundt S, Haug U, Brenner H . Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev. 2007; 16(10):1935-53. DOI: 10.1158/1055-9965.EPI-06-0994. View

Sergeant G, Penninckx F, Topal B . Quantitative RT-PCR detection of colorectal tumor cells in peripheral blood--a systematic review. J Surg Res. 2008; 150(1):144-52. DOI: 10.1016/j.jss.2008.02.012. View

Thorsteinsson M, Jess P . The clinical significance of circulating tumor cells in non-metastatic colorectal cancer--a review. Eur J Surg Oncol. 2011; 37(6):459-65. DOI: 10.1016/j.ejso.2011.01.025. View

Peach G, Kim C, Zacharakis E, Purkayastha S, Ziprin P . Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer. 2010; 102(9):1327-34. PMC: 2865760. DOI: 10.1038/sj.bjc.6605651. View

Tol J, Koopman M, Miller M, Tibbe A, Cats A, Creemers G . Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 2009; 21(5):1006-12. DOI: 10.1093/annonc/mdp463. View

Iinuma H, Okinaga K, Egami H, Mimori K, Hayashi N, Nishida K . Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. Int J Oncol. 2006; 28(2):297-306. View

Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J . Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol. 2011; 29(12):1547-55. DOI: 10.1200/JCO.2010.30.5151. View

Rahbari N, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K . Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010; 138(5):1714-26. DOI: 10.1053/j.gastro.2010.01.008. View

Parkin D . Global cancer statistics in the year 2000. Lancet Oncol. 2002; 2(9):533-43. DOI: 10.1016/S1470-2045(01)00486-7. View

10.

Wang Y, Jatkoe T, Zhang Y, Mutch M, Talantov D, Jiang J . Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol. 2004; 22(9):1564-71. DOI: 10.1200/JCO.2004.08.186. View

11.

Compton C, Fielding L, Burgart L, Conley B, Cooper H, Hamilton S . Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124(7):979-94. DOI: 10.5858/2000-124-0979-PFICC. View

12.

Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J . Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003; 124(2):544-60. DOI: 10.1053/gast.2003.50044. View

13.

Chung K, Kelsen D . Adjuvant Therapy for Stage II Colorectal Cancer: Who and with What?. Curr Treat Options Gastroenterol. 2006; 9(3):272-80. DOI: 10.1007/s11938-006-0046-z. View

14.

Yen L, Yeh Y, Chen C, Wang H, Tsai H, Lu C . Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2009; 15(13):4508-13. DOI: 10.1158/1078-0432.CCR-08-3179. View

15.

Ricci-Vitiani L, Lombardi D, Pilozzi E, Biffoni M, Todaro M, Peschle C . Identification and expansion of human colon-cancer-initiating cells. Nature. 2006; 445(7123):111-5. DOI: 10.1038/nature05384. View

16.

Todaro M, Francipane M, Medema J, Stassi G . Colon cancer stem cells: promise of targeted therapy. Gastroenterology. 2010; 138(6):2151-62. DOI: 10.1053/j.gastro.2009.12.063. View

17.

ENGELL H . [Cancer cells in the circulating blood; a clinical study on the occurrence of cancer cells in the peripheral blood and in venous blood draining the tumour area at operation]. Ugeskr Laeger. 1955; 117(25):822-3. View

18.

Riethdorf S, Wikman H, Pantel K . Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer. 2008; 123(9):1991-2006. DOI: 10.1002/ijc.23825. View

19.

Richardson G, Robson C, Lang S, Neal D, Maitland N, Collins A . CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci. 2004; 117(Pt 16):3539-45. DOI: 10.1242/jcs.01222. View

20.

Visvader J, Lindeman G . Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8(10):755-68. DOI: 10.1038/nrc2499. View